Mizuho analyst Salim Syed joins Analyst Thursdays to talk about this week’s news from Cytokinetics, Gilead, and more

blonca9
Jan 25, 2024
1 min read

Salim Syed discusses this morning’s FOREST-HCM update, Gilead’s Trodelvy news, CRISPR’s allo CAR-T pivot, BridgeBio’s possible reaction to HELIOS-B, and Vaxcyte’s pneumococcal vaccine readout coming up later this year.

Recent Posts

See All

As federal funding for cancer research has been jeopardized at NIH and academia, Parker Institute for Cancer Immunotherapy is one private institution ready to step up and broaden its impact

Mount Sinai has embraced AI as a drug discovery tool by launching this month its new AI Small Molecule Drug Discovery Center - Professor Avner Schlessinger tells us why

Jones Healthcare & Technology Innovation Conference: Jones Research analysts Soumit Roy and Justin Walsh share their take on biotech and comment on companies they cover

Mizuho analyst Salim Syed joins Analyst Thursdays to talk about this week’s news from Cytokinetics, Gilead, and more

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight